Brevan Howard Capital Management’s AstraZeneca AZN Stock Holding History

Brevan Howard Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.77M	Buy	20,152 +13,402	+199%	+$2.52M	0.03%	455
2026 Q1	$1.33M	Buy	+6,750	New	+$1.3M	0.01%	757
2025 Q4	–	Sell	-6,956	Closed	-$1.07M	–	1794
2025 Q3	$1.07M	Buy	+6,956	New	+$1.05M	﹤0.01%	868

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Brevan Howard Capital Management's AZN Position: Q2 2026 in Review

Brevan Howard Capital Management increased its AstraZeneca (AZN) stake by 199% in Q2 2026, buying an estimated $2.52M and bringing the position to 20,152 shares worth $3.77M. The position accounts for 0.03% of the portfolio, ranked #455.

Brevan Howard Capital Management first reported a position in AZN in Q3 2025 and has held it in 3 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Brevan Howard Capital Management held 20,152 shares of AstraZeneca worth $3.77M as of Q2 2026.
Brevan Howard Capital Management bought 13,402 AstraZeneca shares in Q2 2026, an estimated $2.52M.
AstraZeneca made up 0.03% of Brevan Howard Capital Management's portfolio in Q2 2026, its #455 holding.
Brevan Howard Capital Management first reported a position in AstraZeneca in Q3 2025 and has held it in 3 quarters since.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.